Cargando…

The Role of Histone Post-Translational Modifications in Merkel Cell Carcinoma

Merkel Cell Carcinoma (MCC) is a rare but highly aggressive form of non–melanoma skin cancer whose 5-year survival rate is 63%. Merkel cell polyomavirus (MCPyV), a small DNA tumor virus, is the etiological agent of MCC. Although representing a small proportion of MCC cases, MCPyV-negative MCCs have...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazziotta, Chiara, Lanzillotti, Carmen, Gafà, Roberta, Touzé, Antoine, Durand, Marie-Alice, Martini, Fernanda, Rotondo, John Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957841/
https://www.ncbi.nlm.nih.gov/pubmed/35350569
http://dx.doi.org/10.3389/fonc.2022.832047
_version_ 1784676818904678400
author Mazziotta, Chiara
Lanzillotti, Carmen
Gafà, Roberta
Touzé, Antoine
Durand, Marie-Alice
Martini, Fernanda
Rotondo, John Charles
author_facet Mazziotta, Chiara
Lanzillotti, Carmen
Gafà, Roberta
Touzé, Antoine
Durand, Marie-Alice
Martini, Fernanda
Rotondo, John Charles
author_sort Mazziotta, Chiara
collection PubMed
description Merkel Cell Carcinoma (MCC) is a rare but highly aggressive form of non–melanoma skin cancer whose 5-year survival rate is 63%. Merkel cell polyomavirus (MCPyV), a small DNA tumor virus, is the etiological agent of MCC. Although representing a small proportion of MCC cases, MCPyV-negative MCCs have also been identified. The role of epigenetic mechanisms, including histone post-translational modifications (PTMs) in MCC, have been only partially determined. This review aims to describe the most recent progress on PTMs and their regulative factors in the context of MCC onset/development, providing an overview of current findings on both MCC subtypes. An outline of current knowledge on the potential employment of PTMs and related factors as diagnostic and prognostic markers, as well as novel treatment strategies targeting the reversibility of PTMs for MCC therapy is provided. Recent research shows that PTMs are emerging as important epigenetic players involved in MCC onset/development, and therefore may show a potential clinical significance. Deeper and integrated knowledge of currently known PTM dysregulations is of paramount importance in order to understand the molecular basis of MCC and improve the diagnosis, prognosis, and therapeutic options for this deadly tumor.
format Online
Article
Text
id pubmed-8957841
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89578412022-03-28 The Role of Histone Post-Translational Modifications in Merkel Cell Carcinoma Mazziotta, Chiara Lanzillotti, Carmen Gafà, Roberta Touzé, Antoine Durand, Marie-Alice Martini, Fernanda Rotondo, John Charles Front Oncol Oncology Merkel Cell Carcinoma (MCC) is a rare but highly aggressive form of non–melanoma skin cancer whose 5-year survival rate is 63%. Merkel cell polyomavirus (MCPyV), a small DNA tumor virus, is the etiological agent of MCC. Although representing a small proportion of MCC cases, MCPyV-negative MCCs have also been identified. The role of epigenetic mechanisms, including histone post-translational modifications (PTMs) in MCC, have been only partially determined. This review aims to describe the most recent progress on PTMs and their regulative factors in the context of MCC onset/development, providing an overview of current findings on both MCC subtypes. An outline of current knowledge on the potential employment of PTMs and related factors as diagnostic and prognostic markers, as well as novel treatment strategies targeting the reversibility of PTMs for MCC therapy is provided. Recent research shows that PTMs are emerging as important epigenetic players involved in MCC onset/development, and therefore may show a potential clinical significance. Deeper and integrated knowledge of currently known PTM dysregulations is of paramount importance in order to understand the molecular basis of MCC and improve the diagnosis, prognosis, and therapeutic options for this deadly tumor. Frontiers Media S.A. 2022-03-08 /pmc/articles/PMC8957841/ /pubmed/35350569 http://dx.doi.org/10.3389/fonc.2022.832047 Text en Copyright © 2022 Mazziotta, Lanzillotti, Gafà, Touzé, Durand, Martini and Rotondo https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Mazziotta, Chiara
Lanzillotti, Carmen
Gafà, Roberta
Touzé, Antoine
Durand, Marie-Alice
Martini, Fernanda
Rotondo, John Charles
The Role of Histone Post-Translational Modifications in Merkel Cell Carcinoma
title The Role of Histone Post-Translational Modifications in Merkel Cell Carcinoma
title_full The Role of Histone Post-Translational Modifications in Merkel Cell Carcinoma
title_fullStr The Role of Histone Post-Translational Modifications in Merkel Cell Carcinoma
title_full_unstemmed The Role of Histone Post-Translational Modifications in Merkel Cell Carcinoma
title_short The Role of Histone Post-Translational Modifications in Merkel Cell Carcinoma
title_sort role of histone post-translational modifications in merkel cell carcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957841/
https://www.ncbi.nlm.nih.gov/pubmed/35350569
http://dx.doi.org/10.3389/fonc.2022.832047
work_keys_str_mv AT mazziottachiara theroleofhistoneposttranslationalmodificationsinmerkelcellcarcinoma
AT lanzillotticarmen theroleofhistoneposttranslationalmodificationsinmerkelcellcarcinoma
AT gafaroberta theroleofhistoneposttranslationalmodificationsinmerkelcellcarcinoma
AT touzeantoine theroleofhistoneposttranslationalmodificationsinmerkelcellcarcinoma
AT durandmariealice theroleofhistoneposttranslationalmodificationsinmerkelcellcarcinoma
AT martinifernanda theroleofhistoneposttranslationalmodificationsinmerkelcellcarcinoma
AT rotondojohncharles theroleofhistoneposttranslationalmodificationsinmerkelcellcarcinoma
AT mazziottachiara roleofhistoneposttranslationalmodificationsinmerkelcellcarcinoma
AT lanzillotticarmen roleofhistoneposttranslationalmodificationsinmerkelcellcarcinoma
AT gafaroberta roleofhistoneposttranslationalmodificationsinmerkelcellcarcinoma
AT touzeantoine roleofhistoneposttranslationalmodificationsinmerkelcellcarcinoma
AT durandmariealice roleofhistoneposttranslationalmodificationsinmerkelcellcarcinoma
AT martinifernanda roleofhistoneposttranslationalmodificationsinmerkelcellcarcinoma
AT rotondojohncharles roleofhistoneposttranslationalmodificationsinmerkelcellcarcinoma